Guardant Health, Jabil, NeoGenomics, Darden, Cormedix Insider Moves

Insiders have been trading these 5 stocks: ((GH)), ((JBL)), ((NEO)), ((DRI)) and ((CRMD)). Here is a breakdown of their recent trades and their value.

CPO Terilyn J. Monroe’s recent move at Guardant Health has drawn investor attention after she sold 8,571 shares of the company’s stock, a transaction valued at $977,839. Such a sizable sale from a Chief People Officer can prompt questions about internal sentiment or personal portfolio rebalancing, especially in a sector as volatile as healthcare technology. While insider selling does not automatically signal trouble, the nearly one-million-dollar value of this trade may cause shareholders to watch future filings and operational updates from Guardant Health more closely.

Jabil has seen notable insider activity from two senior leaders: SVP, IR and Corporate Affairs Adam E. Berry and EC Mark Mondello. Berry sold 1,596 shares of Jabil stock in a deal worth $404,107, while Mondello executed a much larger sale of 17,200 shares, totaling $4,300,002. Together, these transactions represent a meaningful cash-out by top executives, which could reflect profit-taking after strong performance or strategic personal financial planning. Investors in Jabil may interpret the combined sale value of $4,704,109 as a sign to revisit valuation and monitor upcoming earnings for confirmation of the company’s trajectory.

At NeoGenomics, Pres & COO Warren Stone has also been active on the selling side, disposing of 22,128 shares of company stock for a total of $276,600. For a president and chief operating officer, such a transaction can be part of a pre-planned selling program or a response to recent stock price movements. The relatively modest dollar amount compared with some larger-cap peers still represents a significant block of shares, and market watchers may view Stone’s sale as a data point when assessing confidence in NeoGenomics’ operational outlook and growth plans.

Darden Restaurants has joined the insider-selling trend with Director Rajesh Vennam offloading 6,774 shares in a transaction valued at $1,450,381. For a board member, selling more than a million dollars’ worth of stock can signal portfolio diversification or a belief that the current share price fairly reflects the company’s near-term prospects. With Darden Restaurants operating in a consumer-driven and sometimes cyclical industry, investors may pay attention to this $1.45 million sale in the context of broader macro conditions, same-store sales performance, and guidance on future earnings.

Cormedix has seen significant insider activity as well, with Executive VP and GM Healthcare Janet Dillione selling 10,000 shares of the company’s stock for $68,800. Although the absolute dollar value is smaller than some of the other transactions noted, the round-lot sale by a senior executive in charge of the healthcare segment can still be meaningful for a smaller-cap or emerging company. Market participants may interpret Dillione’s $68,800 sale as part of normal compensation management, but it will likely be tracked alongside future insider trades and clinical or regulatory milestones that could influence Cormedix’s share price.